Iovance Biotherapeutics, Inc.

251 articles with Iovance Biotherapeutics, Inc.

• Iovance Biotherapeutics Reports First Quarter 2022 Financial Results and Corporate Updates

  5/5/2022

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported first quarter 2022 financial results and corporate updates.

• Iovance Biotherapeutics to Present Translational Data for Lifileucel in Advanced Melanoma at 2022 ASCO Annual Meeting

  4/27/2022

  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that translational data for lifileucel in patients with metastatic melanoma will be highlighted at the upcoming 2022 ASCO Annual Meeting.

• Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 5, 2022

  4/26/2022

  Iovance Biotherapeutics, Inc. will report its first quarter financial results on Thursday, May 5, 2022.

• Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

  4/25/2022

  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present.

• Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Apr 22, 2022

  4/22/2022

  Iovance Biotherapeutics, Inc. announced that on April 21, 2022, the Company approved the grant of inducement stock options covering an aggregate of 323,675 shares of Iovance’s common stock to 34 new non-executive employees.

• Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma

  4/5/2022

  Iovance Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration has provided feedback on April 1, 2022 regarding Iovance’s proposed matrix of potency assays for its upcoming Biologics License Application for lifileucel in metastatic melanoma.

• Iovance Biotherapeutics to Present at Upcoming Conferences - Mar 16, 2022

  3/16/2022

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following conferences in March.

• Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)

  3/15/2022

  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has allowed an Investigational New Drug Application (IND) to proceed for its first genetically modified TIL therapy, IOV-4001.

• Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Mar 15, 2022

  3/15/2022

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that on March 14, 2022, the Company approved the grant of inducement stock options and restricted stock units covering an aggregate of 667,725 shares of Iovance’s common stock to nineteen new non-executive employees.

• Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting

  3/8/2022

  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the acceptance of two abstracts for presentation at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting.

• Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates

  2/24/2022

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, reported fourth quarter and full year 2021 financial results and corporate updates.

• Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Feb 18, 2022

  2/18/2022

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that on February 17, 2022, the Company approved the grant of inducement stock options covering an aggregate of 138,575 shares of Iovance’s common stock to nineteen new non-executive employees.

• Iovance Biotherapeutics to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast on Thursday, February 24, 2022

  2/11/2022

  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year financial results on Thursday, February 24, 2022.

• Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Jan 21, 2022

  1/21/2022

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that on January 21, 2022, the Company approved the grant of inducement stock options covering an aggregate of 117,000 shares of Iovance’s common stock to thirteen new non-executive employees.

• Iovance Biotherapeutics Announces Raj K. Puri, M.D., Ph.D. to Join Leadership Team

  1/10/2022

  Iovance Biotherapeutics, Inc. today announced that Raj K. Puri, M.D., Ph.D., will join the Company as Executive Vice President, Regulatory Strategy and Translational Medicine.

• Iovance Biotherapeutics to Present Data on Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®

  1/7/2022

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will present data on Iovance tumor-infiltrating lymphocyte cell therapy at the upcoming Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, to be held February 2 – 6, 2022 in Salt Lake City, Utah, and virtually.

• Iovance Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022

  1/6/2022

  Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Fred Vogt, PhD, Esq., Interim Chief Executive Officer, President and General Counsel of Iovance, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30 a.m. ET.

• Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Dec 17, 2021

  12/17/2021

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that on December 16, 2021, the Company approved the grant of inducement stock options covering an aggregate of 107,900 shares of Iovance’s common stock to eleven new non-executive employees.

• Iovance Biotherapeutics to Present at Upcoming Conferences - Dec 07, 2021

  12/7/2021

  Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced participation in the following conferences in December.

• Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

  11/19/2021

  Iovance Biotherapeutics, Inc. today announced that on November 18, 2021 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 168,575 shares of Iovance’s common stock to seven new non-executive employees.